QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the release of its Sustainability Report 2022, emphasizing its
unwavering focus on driving positive change for society through its
goals for Environment, Social and Governance (ESG) metrics.
The report showcases QIAGEN’s strategic approach
towards sustainable transformation, including its ambitious
emissions reduction goals, diversity and inclusion initiatives, and
efforts to expand global access to vital medical testing.
“We remain steadfast in our commitment to
driving positive change for the planet and its people. As a leading
company in life science research and molecular diagnostics, our
determination to advance science and improve healthcare access has
never been stronger,” said Thierry Bernard, CEO of QIAGEN. “Our
annual ESG report not only showcases our progress in environmental,
social, and governance efforts but also serves as a testament to
the unwavering dedication of our more than 6,000 QIAGENers
worldwide, who work tirelessly to make improvements in life
possible.”
Action for the environment
In early 2023, QIAGEN’s emissions reduction
targets were validated by the Science Based Targets initiative
(SBTi), positioning it among the few companies in its sector with a
verified net-zero science-based target. The company has committed
to achieving net-zero greenhouse gas (GHG) emissions by 2050, using
2020 as the base year. In 2022, QIAGEN made significant strides,
reporting a 20% decrease in Scope 1 and 2 emissions and a 13%
reduction in Scope 3 emissions compared to 2021. QIAGEN also
surpassed its target for a 9% reduction in plastic usage, achieving
a 16.5% decrease. Initiatives to reduce plastic include
eco-friendly transport boxes in the EMEA region and replacing
expandable polystyrene (EPS) coolers with environmentally friendly
packaging at an initial US site.
Action for people and society
In 2022, QIAGEN continued to provide access to
life-saving Sample to Insight solutions to communities worldwide.
For example, more than 16 million QuantiFERON-TB tuberculosis tests
were performed globally, with significant contributions to
high-burden, low-resource countries such as Uganda, Democratic
Republic of the Congo, Kenya, Malawi, Indonesia, India, and
Brazil.
QIAGEN was listed in the Global Disability
Equality Index for the first time in 2022 and will use the results
to identify and implement specific actions to better promote equity
in its workforce. The company also increased the participation of
women in leadership roles from 28% in 2018 to 35% in 2022 and aims
to achieve 36% or more by 2023.
Action for best practices in
governance
QIAGEN strives to ensure that its suppliers and
customers share the same values and continues to promote
responsible and ethical business conduct combined with respect for
human rights as a fundamental value.
QIAGEN introduced measures in 2022 to ensure
that its products are used ethically in accordance with its Human
Rights Policy. Additionally, the company launched a new supplier
policy that requires suppliers to meet the expectations on
environmental protection, labor rights, health and safety, and
corruption. By the end of 2022, the top 95% of suppliers by
expenditure had signed the policy, and all suppliers that accept
purchase orders from 2023 need to agree to comply with the policy.
In 2022, 95% of QIAGEN’s overall purchasing volume came from OECD
countries.
ISS-ESG rating increased, QIAGEN continues
among top industry leaders
QIAGEN has been recognized for its ongoing
commitment to sustainability and responsible business practices
with a recent ESG rating upgrade from ISS-ESG. The independent
rating agency has elevated QIAGEN’s rating from C+ to B-,
reaffirming its “Prime” status and placing it among the top 10% of
all companies in the “Health Care Equipment & Supplies”
industry. QIAGEN’s ESG performance has also been acknowledged
by other independent rating agencies. MSCI ESG Research gave QIAGEN
a grade A in its rating, and Sustainalytics ESG Risk Ratings placed
the company in the low-risk group.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
June 30, 2023, QIAGEN employed more than 6,100 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
pr@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024